Rx Industry Must Change “Mission” To Prepare For Medicare – Scully
Executive Summary
The Medicare prescription drug benefit that begins in 2006 will fundamentally change the mission of pharmaceutical companies, former Centers for Medicare & Medicaid Services Administrator Tom Scully told the Washington Research Group's annual symposium in Washington, D.C. Nov. 5
You may also be interested in...
Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers
Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment
Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers
Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment
Medicare Rx Regions Favor Large Insurers, Small PBMs
The decision to create 34 separate regions for stand-alone drug plans under Medicare Part D is intended to encourage more sponsors to participate in the program, Centers for Medicare & Medicaid Services Administrator Mark McClellan said during a Dec. 6 press conference